Qkine

Qkine

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $11.3M

Overview

Qkine is a private, revenue-generating biotechnology tools company providing essential, high-quality protein reagents to the life sciences research and development sector. Operating from Cambridge, UK, its core business is the manufacturing and sale of optimized growth factors and cytokines, with a focus on supporting advanced cell culture systems like stem cells and organoids. The company positions itself as a critical enabler for emerging fields such as cellular agriculture, organ-on-a-chip, and cell therapy by guaranteeing bioactivity and lot-to-lot consistency. Its products are manufactured to GMP-grade equivalent standards, making them suitable for translational and pre-clinical applications.

Cell TherapyRegenerative Medicine

Technology Platform

Animal-free recombinant protein manufacturing platform with protein engineering for enhanced bioactivity, stability, and purity. Includes GMP-grade equivalent production under ISO standards.

Funding History

2
Total raised:$11.3M
Series A$8.5M
Seed$2.8M

Opportunities

The company is positioned to capitalize on the explosive growth in organoid research, cell therapy development, and emerging bio-engineering fields like cellular agriculture, all of which require high-quality, defined protein components.
Its move into supplying GMP-grade equivalent materials opens the significantly larger market of pre-clinical and clinical-stage biopharma manufacturing.

Risk Factors

Key risks include intense competition from large, established life science tools companies, dependence on the continued growth and funding of niche research areas, and execution challenges in scaling manufacturing and quality systems to meet clinical-grade demand.
As a UK-based manufacturer, it may also face supply chain and cost pressures.

Competitive Landscape

Qkine competes in the research reagents space against giants like Thermo Fisher, Merck, and STEMCELL Technologies, as well as numerous specialty protein suppliers. Its differentiation is based on superior bioactivity, application-specific optimization, and a focus on animal-free, high-purity formats for advanced cell culture, rather than breadth of catalog or lowest price.